[go: up one dir, main page]

MX2020012595A - Composiciones farmaceuticas topicas. - Google Patents

Composiciones farmaceuticas topicas.

Info

Publication number
MX2020012595A
MX2020012595A MX2020012595A MX2020012595A MX2020012595A MX 2020012595 A MX2020012595 A MX 2020012595A MX 2020012595 A MX2020012595 A MX 2020012595A MX 2020012595 A MX2020012595 A MX 2020012595A MX 2020012595 A MX2020012595 A MX 2020012595A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
patient
relates
topical pharmaceutical
present
Prior art date
Application number
MX2020012595A
Other languages
English (en)
Inventor
Mary BEDARD
Michael Quinn DOHERTY
Jon D Lenn
Leandro L Santos
Sujatha D Sonti
Joey Roger THOMAS
Justin E Whiteman
Jain Piyush
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56081527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020012595(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Publication of MX2020012595A publication Critical patent/MX2020012595A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas tópicas en emulsión que comprenden una cantidad terapéuticamente eficaz de 3,5-Dihidroxi-4-isopropil-trans-estilbeno, o una de sus sales farmacéuticamente aceptables, una fase oleosa, una fase acuosa, un tensoactivo, y un antioxidante, y en donde la composición en emulsión es homogénea y/o el ingrediente activo se solubiliza en la fase oleosa; la invención se refiere también a métodos para tratar una afección o trastorno dermatológico en un paciente mediante la administración de las presentes composiciones a la piel del paciente.
MX2020012595A 2015-05-21 2017-11-17 Composiciones farmaceuticas topicas. MX2020012595A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562165097P 2015-05-21 2015-05-21
US201662324450P 2016-04-19 2016-04-19

Publications (1)

Publication Number Publication Date
MX2020012595A true MX2020012595A (es) 2021-02-09

Family

ID=56081527

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014804A MX377629B (es) 2015-05-21 2016-05-19 Composiciones farmacéuticas tópicas.
MX2020012595A MX2020012595A (es) 2015-05-21 2017-11-17 Composiciones farmaceuticas topicas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017014804A MX377629B (es) 2015-05-21 2016-05-19 Composiciones farmacéuticas tópicas.

Country Status (35)

Country Link
US (5) US10195160B2 (es)
EP (2) EP3297605B1 (es)
JP (4) JP6863904B2 (es)
KR (2) KR20240090730A (es)
CN (2) CN107666902B (es)
AU (2) AU2016263161B2 (es)
BR (1) BR112017024934A8 (es)
CA (1) CA2986251A1 (es)
CL (1) CL2017002939A1 (es)
CO (1) CO2017011795A2 (es)
CR (1) CR20170528A (es)
CY (1) CY1125318T1 (es)
DK (1) DK3297605T3 (es)
DO (1) DOP2017000270A (es)
EA (1) EA038624B1 (es)
ES (1) ES2914112T3 (es)
HR (1) HRP20220670T1 (es)
HU (1) HUE059066T2 (es)
IL (3) IL316851A (es)
JO (1) JO3680B1 (es)
LT (1) LT3297605T (es)
MX (2) MX377629B (es)
PE (1) PE20180038A1 (es)
PH (1) PH12017502092A1 (es)
PL (1) PL3297605T3 (es)
PT (1) PT3297605T (es)
RS (1) RS63402B1 (es)
SG (1) SG11201708666RA (es)
SI (1) SI3297605T1 (es)
SM (1) SMT202200224T1 (es)
TW (1) TWI705831B (es)
UA (1) UA125500C2 (es)
UY (1) UY36682A (es)
WO (1) WO2016185428A1 (es)
ZA (1) ZA202007965B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI705831B (zh) 2015-05-21 2020-10-01 瑞士商德瑪凡特科學有限公司 局部醫藥組成物
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
WO2019094934A1 (en) 2017-11-10 2019-05-16 Dermavant Sciences GmbH Process for preparing tapinarof
CN109085257B (zh) * 2018-07-05 2021-04-06 中央民族大学 一种同时定量检测小鼠血浆中黄芪甲苷-iv、环黄芪醇的方法
MX368750B (es) * 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
WO2020214855A1 (en) 2019-04-17 2020-10-22 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
MX2021012874A (es) * 2019-05-15 2021-11-17 Leo Pharma As Tratamiento del lupus eritematoso cutaneo.
US20200383887A1 (en) * 2019-06-04 2020-12-10 L'oreal Oxygenate skin treatment system
BR112021026532A2 (pt) 2019-06-26 2022-05-24 Locus Oil Ip Company Llc Composições multifuncionais compreendendo ácidos concentrados para recuperação melhorada de petróleo e gás
MX2022000960A (es) * 2019-07-24 2022-03-22 Sol Gel Tech Ltd Tratamiento de trastornos de la piel con composiciones topicas de tapinarof-inhibidor de egfr.
WO2021059283A1 (en) * 2019-09-26 2021-04-01 Sol-Gel Technologies Ltd. Treatment of cutaneous adverse effects caused by oncological therapy with topical tapinarof compositions
WO2021059281A1 (en) * 2019-09-26 2021-04-01 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
EP4054526A4 (en) * 2019-11-06 2023-05-24 Sol-Gel Technologies Ltd. METHOD FOR TREATMENT OF PALMOPLANTARIAL KERATODERMA
US20230000786A1 (en) * 2019-11-24 2023-01-05 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical compositions comprising tapinarof and a pde4 inhibitor
GB202000167D0 (en) * 2020-01-07 2020-02-19 Cytovation As Composition for treatment of neoplastic lesions
US11154486B2 (en) 2020-02-14 2021-10-26 William M. Yarbrough Foundation Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
US11191708B2 (en) * 2020-02-17 2021-12-07 William M. Yarbrough Foundation Sodium lauroyl sarcosinate containing detergent compositions
AU2021296867A1 (en) * 2020-06-24 2023-01-19 Dermavant Sciences GmbH Topical pharmaceutical compositions
AU2021300281A1 (en) * 2020-06-30 2023-02-02 Dermira, Inc. RORγt inhibitors and topical uses thereof
CA3208742A1 (en) * 2021-02-17 2022-08-25 David Scott Rubenstein Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
IL305451A (en) 2021-02-25 2023-10-01 Alphyn Biologics Llc Composition for treatment of topical dermatological bacterial skin conditions
CN113797159A (zh) * 2021-10-22 2021-12-17 冠昊生物科技股份有限公司 一种本维莫德乳膏剂及其制备方法和用途
WO2024050431A2 (en) * 2022-08-30 2024-03-07 Dermavant Sciences GmbH Tapinarof and analogs thereof for use in treating ahr mediated diseases
WO2024124206A1 (en) * 2022-12-08 2024-06-13 Hairdao Payments Llc Topical compositions for treating and preventing hair loss and hair graying
WO2025031935A1 (en) 2023-08-04 2025-02-13 Sandoz Ag Crystalline forms of tapinarof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5111748A (en) 1974-07-16 1976-01-30 Taisho Pharmaceutical Co Ltd Suchirubenjudotaino seizoho
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
JPS58159410A (ja) 1982-03-18 1983-09-21 Mitsubishi Chem Ind Ltd 抗炎症剤
WO1990014837A1 (en) * 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5008100A (en) 1989-08-11 1991-04-16 Elizabeth Arden Co., Division Of Conopco, Inc. Oil-in-water emulsions containing polyethylene
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
AU7513994A (en) 1993-07-27 1995-02-28 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria (xenorhabdus) and (photorhabdus) spp.
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
JPH1072330A (ja) 1996-09-03 1998-03-17 Kansai Kouso Kk チロシナーゼ活性阻害剤及び化粧料
JPH1143436A (ja) * 1997-07-25 1999-02-16 Showa Denko Kk 末梢血流障害予防・治療剤
EP1987809A1 (en) 1998-02-10 2008-11-05 Shiseido Co., Ltd. Oil-in-water type emulsion composition enthaltend Retinoide
SE9800729L (sv) 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
FR2777183B1 (fr) 1998-04-10 2001-03-02 Oreal Utilisation d'au moins un hydroxystilbene dans une composition destinee a favoriser la desquamation de la peau et composition le comprenant
AU4084599A (en) 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
DE19842730A1 (de) * 1998-09-18 2000-03-23 Beiersdorf Ag Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl
FR2785284B1 (fr) 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US20020054895A1 (en) * 1999-07-23 2002-05-09 Alwyn Company, Inc. Allantoin-containing skin cream
US7321050B2 (en) * 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
CN1319959C (zh) * 1999-12-06 2007-06-06 天济药业（深圳）有限公司 抗发炎、治疗牛皮癣和抑制蛋白质致活酶的羟基芪、芪衍生物及其类似物
FR2811564B1 (fr) * 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
CN101434517B (zh) 2001-01-18 2014-08-27 北京文丰天济医药科技有限公司 治疗免疫疾病的1，2-二苯基乙烯衍生物
US20030073712A1 (en) 2001-07-23 2003-04-17 Bing Wang Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
RU2212763C2 (ru) * 2001-08-16 2003-09-20 Общество с ограниченной ответственностью "Подсолнечник Технологии" Система открытой оптической связи
MXPA04008818A (es) * 2002-03-12 2004-11-26 Playtex Products Inc Composiciones de locion.
US20040202634A1 (en) * 2003-03-19 2004-10-14 L'oreal Composition useful for cosmetic or dermatological use containing a block copolymer
EA011244B1 (ru) 2004-03-18 2009-02-27 Панацея Биотек Лтд. Новые композиции для местной доставки
US20060018861A1 (en) * 2004-07-23 2006-01-26 Minghua Chen Skin care composition
ES2311236T3 (es) * 2004-10-19 2009-02-01 The Boots Company Plc Composiciones cosmeticos.
US20060246098A1 (en) * 2005-03-16 2006-11-02 Srinivasa Rao Stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same
KR20070057660A (ko) * 2005-12-01 2007-06-07 롬 앤드 하아스 컴패니 활성물을 안정시키기 위한 수성 폴리머 분산액
FR2898498B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
US20080206155A1 (en) * 2006-11-14 2008-08-28 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
EP1930499A1 (en) * 2006-12-08 2008-06-11 Cognis IP Management GmbH Tissue paper comprising a softening lotion
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2009108762A2 (en) 2008-02-26 2009-09-03 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US8226965B2 (en) * 2008-04-25 2012-07-24 Nanobio Corporation Methods of treating fungal, yeast and mold infections
JP2009291133A (ja) * 2008-06-05 2009-12-17 Snow Brand Milk Prod Co Ltd チーズ食品
SG173563A1 (en) 2009-02-25 2011-09-29 Stiefel Res Australia Pty Ltd Topical foam composition
WO2011064631A1 (en) * 2009-10-02 2011-06-03 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
CN101822638A (zh) * 2009-12-01 2010-09-08 河北科技大学 二苯乙烯类化合物的纳米乳及其制备方法
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
US8992954B2 (en) * 2010-03-01 2015-03-31 Photocure Asa Compositions comprising a derivative of 5-aminolevulinic acid
PH12013500783A1 (en) * 2010-10-21 2022-03-30 Cadila Healthcare Ltd Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
WO2012075319A2 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical cream compositions and methods of use
CA2840403A1 (en) 2011-06-27 2013-01-03 Galderma Research & Development New th17 differentiation markers for acne and uses thereof
US20130224268A1 (en) 2012-02-27 2013-08-29 Newgen Biopharma Corp. Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
CN102657610A (zh) 2012-05-11 2012-09-12 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯微乳剂及其制备方法
CN102657602B (zh) 2012-05-22 2013-08-07 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯壳聚糖凝胶剂及其制备方法
US9433680B2 (en) * 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CN103315958B (zh) * 2013-07-19 2014-10-29 河北科技大学 苯烯莫德纳米乳及其制备方法
WO2015085143A2 (en) 2013-12-06 2015-06-11 Stc.Unm Therapeutic agents for skin diseases and conditions
CN103992212B (zh) * 2014-05-29 2015-07-01 河北科技大学 顺式苯烯莫德的合成方法及顺式苯烯莫德的应用
EP3229840B1 (en) 2014-12-12 2020-09-09 Dermavant Sciences GmbH 3,5-dihydroxy-4-isopropyl-trans-stilbene for use in the topical treatment of acne
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
TWI705831B (zh) 2015-05-21 2020-10-01 瑞士商德瑪凡特科學有限公司 局部醫藥組成物
WO2019094934A1 (en) 2017-11-10 2019-05-16 Dermavant Sciences GmbH Process for preparing tapinarof

Also Published As

Publication number Publication date
JO3680B1 (ar) 2020-08-27
JP7531658B2 (ja) 2024-08-09
EP4094752A1 (en) 2022-11-30
US20190151255A1 (en) 2019-05-23
PE20180038A1 (es) 2018-01-09
NZ736602A (en) 2024-10-25
DOP2017000270A (es) 2017-12-15
KR20240090730A (ko) 2024-06-21
BR112017024934A2 (pt) 2018-07-31
US11622945B2 (en) 2023-04-11
US10195160B2 (en) 2019-02-05
US20190192445A1 (en) 2019-06-27
TWI705831B (zh) 2020-10-01
CY1125318T1 (el) 2024-12-13
CN107666902A (zh) 2018-02-06
AU2019203627A1 (en) 2019-06-13
US20190192446A1 (en) 2019-06-27
CL2017002939A1 (es) 2018-03-16
UA125500C2 (uk) 2022-04-13
IL316851A (en) 2025-01-01
PH12017502092A1 (en) 2018-05-07
US11612573B2 (en) 2023-03-28
KR102669247B1 (ko) 2024-05-27
SI3297605T1 (sl) 2022-08-31
RS63402B1 (sr) 2022-08-31
CN114042041A (zh) 2022-02-15
MX377629B (es) 2025-03-10
IL255203A0 (en) 2017-12-31
KR20180008490A (ko) 2018-01-24
IL282304B1 (en) 2024-12-01
SMT202200224T1 (it) 2022-07-21
ES2914112T3 (es) 2022-06-07
PL3297605T3 (pl) 2022-07-11
JP6863904B2 (ja) 2021-04-21
IL282304B2 (en) 2025-04-01
CN107666902B (zh) 2021-09-21
CA2986251A1 (en) 2016-11-24
JP2024153800A (ja) 2024-10-29
DK3297605T3 (da) 2022-06-07
TW201705940A (zh) 2017-02-16
CR20170528A (es) 2018-01-22
LT3297605T (lt) 2022-06-27
EA201792559A1 (ru) 2018-04-30
UY36682A (es) 2016-12-30
WO2016185428A1 (en) 2016-11-24
HK1245074A1 (en) 2018-08-24
JP2021105027A (ja) 2021-07-26
AU2016263161A1 (en) 2017-11-16
AU2019203627B2 (en) 2020-12-24
JP2023113829A (ja) 2023-08-16
JP2018515561A (ja) 2018-06-14
US10426743B2 (en) 2019-10-01
HUE059066T2 (hu) 2022-10-28
IL282304A (en) 2021-05-31
EP3297605A1 (en) 2018-03-28
HRP20220670T1 (hr) 2022-08-19
CN114042041B (zh) 2023-08-22
PT3297605T (pt) 2022-05-30
IL255203B (en) 2021-05-31
ZA202007965B (en) 2022-12-21
CO2017011795A2 (es) 2018-02-28
US20160338973A1 (en) 2016-11-24
US20200101027A1 (en) 2020-04-02
MX2017014804A (es) 2018-02-15
SG11201708666RA (en) 2017-12-28
US11458108B2 (en) 2022-10-04
BR112017024934A8 (pt) 2021-03-30
EP3297605B1 (en) 2022-05-04
AU2016263161B2 (en) 2019-02-28
EA038624B1 (ru) 2021-09-24

Similar Documents

Publication Publication Date Title
MX2020012595A (es) Composiciones farmaceuticas topicas.
BR102016017090B8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
BR112018003892A2 (pt) ?composição farmacêutica e método para a redução da gordura?
BR112015021334A2 (pt) formulações oculares para entrega de droga ao segmento posterior do olho
CL2019002172A1 (es) Agente terapéutico para enfermedades del hígado.
AR096402A1 (es) Medicamento de metformina y dihidroquercetina
MX369474B (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
AR117730A1 (es) Composición para relajación muscular
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
BR112014033088A2 (pt) composição para prevenção ou tratamento de colite compreendendo s-alil-l-cisteína como ingrediente ativo, e preparação médica compreendendo a mesma
CL2018003268A1 (es) Ácidos carboxílicos para tratar/prevenir una enfermedad de la piel.
BR112017006647A2 (pt) composição cosmética e/ou farmacêutica em forma de dispersão, método para preparação da mesma e utilização para o tratamento da pele
AR104699A1 (es) Composición farmacéutica tópica en emulsión y su uso para fabricar un medicamento
MX2022015792A (es) Composiciones farmaceuticas topicas.
CL2018003269A1 (es) Ácidos carboxílicos para aplicación en la primera infancia.
CR20160116A (es) Método para tratar onicomicosis con hidroxipropil quitasano
CL2020000356A1 (es) Composiciones farmacéuticas.
CL2017000088A1 (es) Nueva combinación fija de adapaleno y peróxido de benzoílo para el tratamiento del acné grave.
PH12017501796A1 (en) Dry eye therapeutic agent comprising nandrolone or ester thereof or methenolone or ester thereof as an active ingredient